Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts
NCT ID: NCT05781841
Last Updated: 2024-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2023-04-15
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Human papilloma virus is small non enveloped viruses that contain a double-stranded DNA genome. There are more than 200 HPV genotypes are reported, however, the high-risk types, including HPV genotype-16 (HPV16), 18, 31, and 45, are the causes of 80% of cervical cancers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts
NCT05100043
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
NCT05291845
Study With a Topical Gel to Treat Common Warts in Adults
NCT00117871
Evaluation of the Efficacy of Cryotherapy Combined With Intralesional Hepatitis B Virus Vaccine Versus Either Therapy in the Treatment of Multiple Cutaneous Warts :a Comparative Study
NCT05902624
Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
NCT05409365
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
About 90% of HPV infections are eliminated within two years due to an efficient immune response. In the form of correct activation of the elements of the innate immune response, such as macrophages, polymorphonuclear cells, natural killer (NK) cells, which release immunomodulatory molecules that help control the infection. In addition, HPV-infected keratinocytes may act as non-professional antigen-presenting cells to promote the clearance of infected cells through the secretion of antiviral and pro-inflammatory mediators.
Interferon (IFN) belongs to a family of inducible cytokines which promote an"antiviral state" in infected cells and neighboring cells through the activation of interferon-stimulated genes (ISG). Three IFN types have been identified (type I, II and III), of which I and III are involved in the innate immune response. Type I IFNs include IFN-α, IFN-β, IFN-ɛ, IFN-κ and IFN-ω.
Most type I IFNs are induced through the binding of viral products to pattern recognition receptors, leading to activation of interferon response factors to drive the synthesis of IFN molecules. After secretion, type I IFNs bind to its receptor, which induces the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and STAT2, which then translocate to the nucleus to induce transcription of (ISGs).
The antiviral effects of IFN-I are mediated by inducing several (ISGs) which impair viral replication through inhibition of protein translation and degradation of viral RNA. ISGs also activate the survival of innate and adaptive immune cells including dendritic cells, macrophages, NK cells and T cells. So, IFN-I helps to control the infections.
During the viral infection process, cytokines trigger and deal with inflammation. However, excessive production of cytokines can cause a cytokine storm, and excessive host innate immune response can also damage the body. Therefore, the suppressor of cytokine signaling proteins with negative feedback regulation ability, prevents the excessive secretion of cytokines from harming the host cell. These intracellular protein family is constituted by suppressor of cytokine signaling proteins 1-7, Which are potent endogenous inhibitors of Janus kinase (JAK/ STAT) signal.
The SOCS 3 is mainly involved in the negative feedback regulation of the tyrosine-protein kinase/ STAT signaling. The critical role of SOCS3 is manifested by its binding to both the JAK and the tyrosine kinase receptor, which further inhibits STAT3 phosphorylation. The JAK/STAT pathway transduces extracellular signals to the nucleus. Its activation stimulates cell proliferation, differentiation, migration, and immune challenge. The JAK/STAT signaling pathway plays an important role in viral infection.
The SOCS family are induced by various viral infections, including human immunodeficiency virus-1, hepatitis B and C viruses, herpes simplex virus type 1, respiratory syncytial virus, Ebola virus, influenza A, and coxsackie virus. Influenza A virus inhibits type I IFN signaling through the induction of SOCS3 expression. Newcastle disease virus (NDV) infection activates the expression of SOCS3 at the mRNA and protein level, which is conducive to the virus replication.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with cutaneous warts
Under complete sterile precautions, Skin biopsy will be taken from patients with wart lesion.
The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed
Detection of expression of SOCS3 gene
Detection of expression of SOCS3, in each samples using Real-Time PCR
Detection of expression of IFN-α gene
Detection of expression of IFN-α gene in each samples using Real-Time PCR
Detection of expression of IFN-β gene
Detection of expression of IFN-β gene in each samples using Real-Time PCR
healthy volunteers
Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 2 mm disposable punches .
The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed
Detection of expression of SOCS3 gene
Detection of expression of SOCS3, in each samples using Real-Time PCR
Detection of expression of IFN-α gene
Detection of expression of IFN-α gene in each samples using Real-Time PCR
Detection of expression of IFN-β gene
Detection of expression of IFN-β gene in each samples using Real-Time PCR
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Detection of expression of SOCS3 gene
Detection of expression of SOCS3, in each samples using Real-Time PCR
Detection of expression of IFN-α gene
Detection of expression of IFN-α gene in each samples using Real-Time PCR
Detection of expression of IFN-β gene
Detection of expression of IFN-β gene in each samples using Real-Time PCR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Reham Helal Aboelhamd
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hanan A Assaf, professor
Role: STUDY_CHAIR
Sohag University
Zeinab A Goda, lecturer
Role: STUDY_CHAIR
Sohag University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University Hospital
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Feng M, Xie T, Li Y, Zhang N, Lu Q, Zhou Y, Shi M, Sun J, Zhang X. A balanced game: chicken macrophage response to ALV-J infection. Vet Res. 2019 Mar 6;50(1):20. doi: 10.1186/s13567-019-0638-y.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-23-03-7MS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.